Results 21 to 30 of about 312,536 (265)

Pharmacotherapy of severe asthma [PDF]

open access: yesCurrent Opinion in Pharmacology, 2010
Severe asthma is a complex and heterogeneous phenotype where management can be challenging. While many patients with severe asthma respond to high-dose inhaled corticosteroids in combination with a long-acting beta-agonist, there remains a significant subset of patients that require oral corticosteroids to control symptoms.
Rafael, Firszt, Monica, Kraft
openaire   +2 more sources

Severity of chronic asthma [PDF]

open access: yesThorax, 1998
How is the severity of chronic asthma best assessed and what are the mechanisms that determine its severity? These two questions are difficult to answer because, until we understand what asthma is, it is not possible to describe its severity in a given individual.
A J, Woolcock, D, Dusser, I, Fajac
openaire   +2 more sources

Severe Asthma Toolkit: an online resource for multidisciplinary health professionals—needs assessment, development process and user analytics with survey feedback

open access: yesBMJ Open, 2020
Objectives Severe asthma imposes a significant burden on individuals, families and the healthcare system. New treatment and management approaches are emerging as effective options for severe asthma.
Peter G Gibson   +13 more
doaj   +1 more source

Azithromycin and severe asthma [PDF]

open access: yesThorax, 2013
Brusselle et al 1 performed an interesting academic-based randomised controlled trial Azithromycin for Prevention of Exacerbations in Severe Asthma (AZISAST) of azithromycin 250 mgm taken thrice weekly versus placebo as add-on therapy for 26 weeks in non-smoking patients with severe asthma, defined as Global Initiative for Asthma (GINA) steps 4–5 ...
openaire   +2 more sources

Pathophysiology of severe asthma [PDF]

open access: yesJournal of Allergy and Clinical Immunology, 2000
Although asthma affects nearly 8% of the adult population, most of these patients have mild-to-moderate disease that can be controlled with appropriate treatment. It is estimated, however, that 5% to 10% of patients with asthma have severe disease that is unresponsive to typical therapeutics, including corticosteroids.
W W, Busse   +2 more
openaire   +2 more sources

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India

open access: yesRespirology Case Reports, 2021
Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5).
Venkata Nagarjuna Maturu   +7 more
doaj   +1 more source

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

open access: yesAnnals of Medicine
Background Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients’ characteristics are different from those encountered in asthma ...
Maria Basagaña   +12 more
doaj   +1 more source

Asthma heterogeneity and severity [PDF]

open access: yesWorld Allergy Organization Journal, 2016
Asthma is a common, chronic inflammatory airways disease characterized by a clinical syndrome of bronchial hyperresponsiveness, inflammation, and reversible airflow obstruction. Individuals with asthma can vary widely in clinical presentation, severity, and pathobiology.
Tara F. Carr, Eugene Bleecker
openaire   +3 more sources

Asthma control in severe asthma and occupational exposures to inhalable asthmagens

open access: yesBMJ Open Respiratory Research
Introduction Work-related asthma accounts for ≥25% of asthma in working-age populations, though the relationship between work exposures and symptoms is frequently missed, leading to poor health and employment outcomes.
Mamidipudi Thirumala Krishna   +8 more
doaj   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy